12.72
-0.16 (-1.24%)
| Penutupan Terdahulu | 12.88 |
| Buka | 12.92 |
| Jumlah Dagangan | 774,187 |
| Purata Dagangan (3B) | 2,123,450 |
| Modal Pasaran | 726,119,168 |
| Harga / Jualan (P/S) | 1.03 |
| Harga / Buku (P/B) | 5.21 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| EPS Cair (TTM) | -1.88 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.75% |
| Nisbah Semasa (MRQ) | 17.39 |
| Aliran Tunai Operasi (OCF TTM) | -96.14 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -62.11 M |
| Pulangan Atas Aset (ROA TTM) | -22.56% |
| Pulangan Atas Ekuiti (ROE TTM) | -32.89% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Astria Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -1.75 |
|
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.49% |
| % Dimiliki oleh Institusi | 106.43% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |